Eversept Partners, LP Macrogenics Inc Transaction History

Eversept Partners, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$5.2 - $29.12 $478,389 - $2.68 Million	-91,998 Closed	0 $0
Q1 2020 Nov 08, 2023	SELL	$4.28 - $12.11 $107,000 - $302,750	-25,000 Reduced 21.37%	91,998 $535,000
Q1 2020 May 13, 2020	SELL	$4.28 - $12.11 $107,000 - $302,750	-25,000 Reduced 21.37%	91,998 $535,000
Q4 2019 Nov 08, 2023	SELL	$7.95 - $12.27 $300,716 - $464,125	-37,826 Reduced 24.43%	116,998 $1.27 Million
Q4 2019 Feb 13, 2020	SELL	$7.95 - $12.27 $300,716 - $464,125	-37,826 Reduced 24.43%	116,998 $1.27 Million
Q3 2019 Nov 08, 2023	SELL	$12.44 - $17.48 $445,339 - $625,766	-35,799 Reduced 18.78%	154,824 $1.98 Million
Q3 2019 Nov 13, 2019	SELL	$12.44 - $17.48 $445,339 - $625,766	-35,799 Reduced 18.78%	154,824 $1.98 Million
Q2 2019 Nov 08, 2023	BUY	$14.51 - $19.71 $2.77 Million - $3.76 Million	190,623 New	190,623 $3.23 Million
Q2 2019 Aug 13, 2019	BUY	$14.51 - $19.71 $2.77 Million - $3.76 Million	190,623 New	190,623 $3.24 Million

133

55.5M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $175M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.